Fig. 6: ISL1 promoted ZEB1 expression by H3K4me3 modification through binding SETD7. | Cell Death & Disease

Fig. 6: ISL1 promoted ZEB1 expression by H3K4me3 modification through binding SETD7.

From: ISL1 predicts poor outcomes for patients with gastric cancer and drives tumor progression through binding to the ZEB1 promoter together with SETD7

Fig. 6

a Consensus binding site (TAAT) for ISL1 on the ZEB1 promotor. b Luciferase reporter assay was performed in 293FT cells c, d Sonicated chromatin from the SGC7901 cells with ISL1 knockdown was immunoprecipitated with ISL1 (c) and H3K4me3 antibodies (d). The resulting input and ChIP DNA were characterized with qPCR primers specific for ZEB1 genomic loci to calculate the percentage of coprecipitated DNA relative to the input. e, f Immunoprecipitation and mass spectrometry analysis of cofactors of ISL1. For the coimmunoprecipitation assay, normal IgG served as the negative control. g ChIP and re-ChIP assays. The second ChIP was performed using an antibody against SETD7, and the resulting input and ChIP DNA were characterized with qPCR primers specific for ZEB1 genomic loci to calculate the percentage of coprecipitated DNA relative to the input. h Schematic depicting how ISL1 activate ZEB1 expression in gastric cancer cells. Each bar in the column chart data of bd represents the mean ± SD from three independent experiments in triplicate

Back to article page